News coverage about Mirati Therapeutics (NASDAQ:MRTX) has been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Mirati Therapeutics earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 77 out of 100, indicating that recent press coverage is likely to have an effect on the stock’s share price in the next few days.
MRTX has been the subject of a number of analyst reports. Zacks Investment Research upgraded Mirati Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a research note on Wednesday, May 3rd. Jefferies Group LLC reissued a “hold” rating and set a $5.50 target price on shares of Mirati Therapeutics in a research report on Wednesday, April 12th. Finally, ValuEngine raised shares of Mirati Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 6th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company. Mirati Therapeutics currently has a consensus rating of “Hold” and an average target price of $7.54.
Mirati Therapeutics (NASDAQ MRTX) traded down 2.04% during trading on Friday, hitting $4.80. 153,008 shares of the company’s stock traded hands. The company’s 50 day moving average is $3.91 and its 200-day moving average is $4.56. Mirati Therapeutics has a 12 month low of $2.70 and a 12 month high of $7.22. The stock’s market cap is $119.71 million.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.chaffeybreeze.com/2017/07/30/mirati-therapeutics-nasdaqmrtx-receiving-somewhat-positive-news-coverage-analysis-finds-updated-updated-updated.html.
Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.